Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialPatrick Neven, George W. Sledge, Hope S. Rugo et al.|Breast Cancer Research|2021Cited by 34
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast CancerPatrick Neven, George W. Sledge, Eva‐Maria Grischke et al.|Clinical Cancer Research|2021Cited by 16
Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 TrialPatrick Neven, George W. Sledge, Hope S. Rugo et al.|Research Square|2021Cited by 4
MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.Patrick Neven, George W. Sledge, Stephen Johnston et al.|Journal of Clinical Oncology|2020Cited by 3
Data from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast CancerPatrick Neven, George W. Sledge, Stephen Johnston et al.|Unknown|2023Cited by 0